These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30942448)

  • 1. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
    Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
    Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
    Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells.
    Abate A; Rossini E; Tamburello M; Laganà M; Cosentini D; Grisanti S; Fiorentini C; Tiberio GAM; Scatolini M; Grosso E; Hantel C; Memo M; Berruti A; Sigala S
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34875044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
    Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
    Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
    Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth.
    Trotta F; Avena P; Chimento A; Rago V; De Luca A; Sculco S; Nocito MC; Malivindi R; Fallo F; Pezzani R; Pilon C; Lasorsa FM; Barile SN; Palmieri L; Lerario AM; Pezzi V; Casaburi I; Sirianni R
    Mol Cancer Ther; 2020 Sep; 19(9):1909-1921. PubMed ID: 32546662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
    Lehmann TP; Wrzesiński T; Jagodziński PP
    Mol Med Rep; 2013 Mar; 7(3):893-900. PubMed ID: 23254310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
    J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
    Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
    Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
    Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for adrenocortical carcinoma.
    Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
    Borges KS; Andrade AF; Silveira VS; Marco Antonio DS; Vasconcelos EJR; Antonini SRR; Tone LG; Scrideli CA
    Anticancer Drugs; 2017 Jul; 28(6):634-644. PubMed ID: 28410270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.